FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling

The epidermal growth factor receptor (EGFR) is a clinically validated target in head and neck squamous cell carcinoma (HNSCC), where EGFR-blocking antibodies are approved for first-line treatment. However, as with other targeted therapies, intrinsic/acquired resistance mechanisms limit efficacy. In...

Descripción completa

Detalles Bibliográficos
Autores principales: Daly, C, Castanaro, C, Zhang, W, Zhang, Q, Wei, Y, Ni, M, Young, T M, Zhang, L, Burova, E, Thurston, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290037/
https://www.ncbi.nlm.nih.gov/pubmed/27345413
http://dx.doi.org/10.1038/onc.2016.216

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5290037/
https://www.ncbi.nlm.nih.gov/pubmed/27345413
http://dx.doi.org/10.1038/onc.2016.216

Ejemplares similares